| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/29/2004 | DE10229379A1 EG-VEGF Rezeptor Antagonisten EG-VEGF receptor antagonists |
| 01/29/2004 | CA2498982A1 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer |
| 01/29/2004 | CA2493721A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 01/29/2004 | CA2493544A1 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| 01/29/2004 | CA2493458A1 Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| 01/29/2004 | CA2493341A1 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 01/29/2004 | CA2493202A1 Antitumor compound and therapeutic uses thereof |
| 01/29/2004 | CA2493064A1 Tumor treating combinations, compositions and methods |
| 01/29/2004 | CA2493062A1 Tumor treating composition and methods |
| 01/29/2004 | CA2493000A1 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
| 01/29/2004 | CA2492941A1 Remedy |
| 01/29/2004 | CA2492922A1 Substituted thiophene carboxamide compounds for the treatment of inflammation |
| 01/29/2004 | CA2492878A1 Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| 01/29/2004 | CA2492862A1 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 01/29/2004 | CA2492665A1 Azaindole kinase inhibitors |
| 01/29/2004 | CA2492651A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
| 01/29/2004 | CA2492472A1 Use of urease for inhibiting cancer cell growth |
| 01/29/2004 | CA2492224A1 Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutics |
| 01/29/2004 | CA2492110A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 01/29/2004 | CA2491131A1 Novel compounds as histone deacetylase inhibitors |
| 01/29/2004 | CA2466288A1 Methods of treating conditions associated with an edg-1 receptor |
| 01/28/2004 | EP1384726A2 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 01/28/2004 | EP1384719A1 Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections |
| 01/28/2004 | EP1384712A1 Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity |
| 01/28/2004 | EP1384710A1 Synthesis of heterocyclic compounds containing five- or six-membered rings |
| 01/28/2004 | EP1384488A2 Method and kit for imaging organs and tissues, using labelled antibodies |
| 01/28/2004 | EP1384487A1 Drugs containing genetically modified antibody against ganglioside gd3 |
| 01/28/2004 | EP1384484A1 Use of efrapeptin oligopeptides for inhibition of angiogenesis |
| 01/28/2004 | EP1384477A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases |
| 01/28/2004 | EP1384472A1 Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate |
| 01/28/2004 | EP1384081A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
| 01/28/2004 | EP1383927A2 New polynucleotides and polypeptides of the erythropoietin gene |
| 01/28/2004 | EP1383924A2 Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof |
| 01/28/2004 | EP1383922A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 01/28/2004 | EP1383919A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/28/2004 | EP1383895A2 Polynucleotides and polypeptides of the ifnalpha-5 gene |
| 01/28/2004 | EP1383893A2 Proteins and nucleic acids encoding same |
| 01/28/2004 | EP1383892A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/28/2004 | EP1383884A2 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 01/28/2004 | EP1383872A2 Genetically modified yt cell line and use thereof |
| 01/28/2004 | EP1383802A2 Anti-muc-1 single chain antibodies for tumor targeting |
| 01/28/2004 | EP1383801A1 Antibodies against cancer |
| 01/28/2004 | EP1383800A1 RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
| 01/28/2004 | EP1383798A2 Transporters and ion channels |
| 01/28/2004 | EP1383793A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/28/2004 | EP1383792A2 Sh2 domain binding inhibitors |
| 01/28/2004 | EP1383789A2 Proteins associated with cell growth, differentiation, and death |
| 01/28/2004 | EP1383785A2 Recombinant tumor specific antibody and use thereof |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383778A2 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 01/28/2004 | EP1383772A2 Nitrogen-based camptothecin derivatives |
| 01/28/2004 | EP1383769A2 6-substituted pyrazolo 3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| 01/28/2004 | EP1383766A1 Disubstituted 1,7-guanines |
| 01/28/2004 | EP1383764A1 Ratjadone derivatives for inhibiting cell growth |
| 01/28/2004 | EP1383762A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same |
| 01/28/2004 | EP1383750A2 Urea derivatives as integrin alpha 4 antagonists |
| 01/28/2004 | EP1383746A2 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 01/28/2004 | EP1383743A2 Dual inhibitors of pde 7 and pde 4 |
| 01/28/2004 | EP1383735A1 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof |
| 01/28/2004 | EP1383733A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
| 01/28/2004 | EP1383573A2 Methods and apparatus for treating diseased tissue |
| 01/28/2004 | EP1383551A2 Catheter and implants for the delivery of therapeutic agents to tissues |
| 01/28/2004 | EP1383544A1 Anti-cd19 immunotoxins |
| 01/28/2004 | EP1383543A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/28/2004 | EP1383539A1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 01/28/2004 | EP1383535A2 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof |
| 01/28/2004 | EP1383532A2 Combination therapy |
| 01/28/2004 | EP1383528A2 Epitope sequences |
| 01/28/2004 | EP1383522A2 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of inflammatory skin conditions |
| 01/28/2004 | EP1383521A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| 01/28/2004 | EP1383520A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| 01/28/2004 | EP1383517A1 Use of cationic dextran derivatives for protecting dose-limiting organs |
| 01/28/2004 | EP1383516A1 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 01/28/2004 | EP1383515A1 Activation of natural killer cells by adenosine a3 receptor agonists |
| 01/28/2004 | EP1383513A1 Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
| 01/28/2004 | EP1383511A2 Calcilytic compounds |
| 01/28/2004 | EP1383506A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7 |
| 01/28/2004 | EP1383505A2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
| 01/28/2004 | EP1383504A1 Sustained release drug delivery system containing codrugs |
| 01/28/2004 | EP1383501A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 01/28/2004 | EP1383494A2 Compositions and methods for the prevention and treatment of human prostate cancer |
| 01/28/2004 | EP1383492A1 Molecular conjugates for use in treatment of cancer |
| 01/28/2004 | EP1383491A2 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
| 01/28/2004 | EP1383490A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 01/28/2004 | EP1383481A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 01/28/2004 | EP1383447A1 Stent-based delivery of statins to prevent restenosis |
| 01/28/2004 | EP1383379A1 Restoration of cancer-suppressing functions to neoplastic cells through dna hypomethylation |
| 01/28/2004 | EP1296676B1 Use of indole-3-acetic acid derivatives in medicine |
| 01/28/2004 | EP1217990B1 Cationic dosper virosomes |
| 01/28/2004 | EP1183237B1 Novel antioxidants, preparation methods and uses |
| 01/28/2004 | EP1143946B1 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 01/28/2004 | EP1061944B1 Therapeutic chemokine receptor antagonists |
| 01/28/2004 | EP0914345B1 Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
| 01/28/2004 | EP0763124B1 Method for introducing nucleic acid in higher eukaryotic cells |
| 01/28/2004 | EP0708829B1 A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
| 01/28/2004 | CN1471583A Packaging of positive-strand RNA virus replicon particles |
| 01/28/2004 | CN1471579A CRIPTO tumour polypeptide |
| 01/28/2004 | CN1471535A Tricyclic derivatives of indole with antiangiogenic activity |
| 01/28/2004 | CN1471534A 桥(连)哌嗪衍生物 Bridge (even) piperazine derivatives |
| 01/28/2004 | CN1471527A 喹唑啉衍生物 Quinazoline derivatives |